Inflammation is an essential defense mechanism against harmful stimuli. However, uncontrolled inflammatory mechanisms culminate in disturbed responses that contribute to multiple serious diseases. Besides common synthetic drugs, there is a growing interest in optimizing the use of natural products as therapeutic or protective supplements against inflammatory disorders. Black cumin seed (BCS), or Nigella sativa (Family Ranunculaceae), is widely used as a health-supportive herb in the Middle East, Far East and West Asia. BCS is a rich source of phytochemicals, and studies have reported its promising effects against a variety of metabolic, proliferative, respiratory, and neurological disorders associated with disrupted inflammatory pathways. This review presents an updated comprehensive assessment of BCS’s effects against various inflammatory disorders and highlights the role of BCS’s bioactive constituents in inflammation and oxidative stress pathways. Moreover, it outlines the future possibilities for enhancing therapeutic activity through efficient pharmaceutical formulations. Thorough analysis of international research studies published between the years 1998 and 2023 reveals the promising anti-inflammatory potential of BCS’s bioactive constituents through modulating inflammation and crucial oxidative stress players in inflammatory disorders. Thus, the bioactive constituents of BCS can be further boosted by updated technologies such as nano-incorporation for the improved management of inflammatory diseases.

Background: Acute kidney injury (AKI) is a medical concern that is accompanied by the rapid deterioration of kidney function. It can be triggered by lipopolysaccharide (LPS) of gram-negative bacteria as it activates a complicated immune response, resulting in widespread inflammation and potential organ dysfunction. Black seed oil (BSO) is rich in beneficial constituents and has been widely used owing to its nutritional advantages. Purpose: This research is aimed to investigate the potential protective effects of BSO and its nano-formulation on AKI induced by LPS. It also aimed to compare their anti-inflammatory activity with indomethacin, a known synthetic anti-inflammatory drug. Materials and Methods: Forty-eight mice were placed randomly into 8 groups. A single intraperitoneal (i.p.) injection of 2.5 mg/kg B.W. of LPS was used to trigger inflammation, and pretreatment with BSO and its nano-formulation was at 0.2 mL/kg/day for 14 consecutive days. Indomethacin was used as a reference drug and its efficacy was tested alone or in combination with BSO at lower doses. Renal function was assessed using urea, creatinine, neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1). Also, oxidative and inflammatory markers were assessed by measuring levels of reduced glutathione (GSH), nitric oxide (NO), cyclooxygenase-2 (COX-2), tumor necrosis factor alpha (TNF-α), and toll-like receptor-4 (TLR-4). Histopathological examination of the kidney tissues was also performed. Results: The study showed that BSO and its nano-formulation had anti-inflammatory effects comparable to or better than those of indomethacin. They greatly decreased the oxidative stress and inflammatory markers induced by LPS. Their protective effect against pathological alterations in kidney tissues was significantly noticed. Conclusion: BSO and its nano-formulation could be used as nephroprotective and anti-inflammatory supplements.

Backgrounds and objectives: Microglia play a regulatory role in central nervous system inflammatory diseases, such as Alzheimer’s, Parkinson’s, and multiple sclerosis. Natural remedies like black cumin seeds (Nigella sativa) are rich in bioactive compounds that potentially can modulate inflammatory processes in the brain. In the current work, we studied the protective and anti-inflammatory properties of black cumin seed oil (BCSO) and its nano-form on lipopolysaccharide (LPS)-induced neurotoxicity in mice. Materials and methods: Forty-eight mice were divided randomly into eight groups (n=6), three control groups (negative control, BCSO control, nano-BCSO control), LPS group, and four treatment groups [BCSO+LPS, nano-BCSO+LPS, indomethacin (5 mg/kg)+LPS, BCSO+indomethacin(2.5 mg/kg)+LPS]. At the end of the experiment, the brain tissues were removed for histopathological and biochemical assessments. Malondialdehyde and interleukin (IL)-10 were assessed using enzyme-linked immunosorbent assay while the gene expression of IL-6, toll-like receptor-4, brain-derived neurotrophic factor, nerve growth factor, cyclooxygenase-2, and B-cell lymphoma-2 were assessed by real-time PCR. IL-1β was quantified immunohistochemically along with the histopathological studies of the cerebral cortex of mice brains. Results and conclusions: In our study, BCSO and its nano-form demonstrated a reduction in LPS-induced neurotoxicity, exhibiting comparable or better anti-inflammatory effects to indomethacin. These treatments significantly elevated the gene expression levels of neuroprotective factors brain-derived neurotrophic factor and nerve growth factor in LPS-treated mice. Pretreatment with BCSO and its nano-form reduced the malondialdehyde levels, in addition to gene expressions of cyclooxygenase-2, toll-like receptor-4, IL-6, and B-cell lymphoma-2. Immunohistochemical analysis indicated a decrease in IL-1β with BCSO and the lowering effect of the nano-form was superior. The histopathological studies corroborated with biochemical and molecular findings, suggesting that BCSO and its nano-form attenuated the inflammation and enhanced the microglial antioxidative and anti-inflammatory status. BCSO could enhance the anti-inflammatory activity of indomethacin, so lower doses of indomethacin with BCSO may be suggested for protecting against the adverse effects of high doses of NSAIDs as gastritis. Consequently, BCSO can serve a potential stimulatory supplement of the immunity for neurodegenerative conditions.